Pyc Therapeutics Limited · ASX:PYC

Pyc Therapeutics — Phylogica — Shareholder Meeting (November 2014)

21 slides from Pyc Therapeutics's shareholder meeting presentation, Nov 27, 2014

1. Slide 1: Phylogica 2014 AGM Presentation

   For personal use only Phylogica 2014 AGM Presenta7on (PYC:ASX) Harnessing biodiversity for peptide therapeutics

2. Slide 2: Disclaimer

   Disclaimer The purpose of the presenta.on is to provide an update of the business of Phylogica Limited (ASX:PYC) For personal use only [‘Phylogica’]. These slides have been prepared as a presenta.on aid only and the informa.on they contain may require further explana.on and/or clarifica.on. According

3. Slide 3: 2014 Highlights

   For personal use only 2014 Highlights § Successfully validated powerful intracellular drug delivery plaTorm § Iden.fied ‘Best-­‐in-­‐Class’ Phylomers for delivering drugs inside cells § ‘Value-­‐adding’ strategy to improve intracellular delivery of exis.ng drugs § Launched proprietary cancer prog

4. Slide 4: Corporate Snapshot

   Corporate Snapshot For personal use only Shareholders % Summary B. Hockings 25 ASX PYC Sietsma Holdings 8 Cash (9/14) 4.7m Bonadido 4 Net Burn 3.2m Top 15 55 Market Cap 16m 52 wk low/high 0.1/0.4c Execu&ve Team Shares on issue 1000m Dr Richard Hopkins – CEO Dr Paul WaQ -­‐ CSO Board of Directors Dr

5. Slide 5: Phylogica: focussed on intracellular delivery of biologics

   Phylogica: focussed on intracellular delivery of biologics For personal use only CNS Delivery Cell penetrating Intracellular Drug Vaccines peptides Delivery Cancer Antimicrobials Differen7a7on Product Focus 5

6. Slide 6: Technology Update

   For personal use only Technology Update

7. Slide 7: Majority of drug targets are inside cells

   Majority of drug targets are inside cells Intracellular Drug Targets For personal use only Small Molecule Drugs (10%) Undrugged targets (90%) Biologics? § PYC addressing unmet need to deliver biologic drugs inside cells!

8. Slide 8: Peptides: purpose built for the job

   Pep7des: purpose built for the job For personal use only Large Biologics (Smart drugs) Cell Penetra7ng Targets Phylomer Pep7des Specific (Biologic) Small Molecule Drugs Size 8

9. Slide 9: Cell Penetrating Phylomers: delivering biologics cargoes inside cells

   Cell Penetra7ng Phylomer (CPPs): delivering biologics cargoes inside cells For personal use only Poten7al to expand the druggable landscape by >10-­‐fold!! 9

10. Slide 10: Validation of 'Best in Class' Phylomers for intracellular drug delivery

    For personal use only Valida7on of ‘Best in Class’ Phylomers for intracellular drug delivery 10

11. Slide 11: 'Best-in-class' Phylomers for delivering drugs inside cells

    ‘Best-­‐in-­‐class’ Phylomers for delivering drugs inside cells For personal use only 25-­‐fold High receptor-­‐expressing cells: 50 transfec.on efficiency: 70.3% 10µM protein 40 3µM protein efficiency cells (Q3) (% Green Cells) single cell population 30 ‘Best in Class’ Phylomer CPP % green viable Deliv

12. Slide 12: Applications for Phylogica's 'Best-in-Class' Drug Delivery Solution

    For personal use only Applica7ons for Phylogica’s ‘Best-­‐in-­‐Class’ Drug Deliver Solu7on 12

13. Slide 13: Multiple commercialisation opportunities

    Mul7ple commercialis7on opportuni7es For personal use only ‘Value Adding’ Improve delivery of exis.ng drugs Cell Penetra.ng Phylomers ‘Phylomer Therapeu?cs’ Fully integrated drug delivery/ discovery plaTorm Plalorm Products 13

14. Slide 14: Value Adding: Approaching key potency thresholds

    Value Adding: Approaching key potency thresholds Amount of use only Drug 10 µM Standard Compe7tors CPP_Cargoes Increasing Drug Ac7vity Phylomer CPPs_cargoes For personal 1 µM <1µM = key potency threshold Phylomer 0.1 µM CPPs_toxins 14

15. Slide 15: Phylogica's Oncology Programme

    For personal use only Phylogica’s Oncology Programme Targe7ng Breat Cancer 15

16. Slide 16: Developing Phylomer drugs to treat cancer

    Developing Phylomer drugs to treat cancer For personal use only § Unmet need for drugs against breast cancer targets intractable to conven.onal therapies § Phylogica’s plaTorm accelerates path to drug discovery § Rapid access to high-­‐value commercial inflexion points 16

17. Slide 17: Phylogica's Proprietary Oncology Programme

    Phylogica’s Proprietary Oncology Programme For personal use only Func7onal Program Indica7on Discovery Preclinical Valida7on Stat 5/3 Breast Cancer Myc Breast Cancer YB1 Breast Cancer

18. Slide 18: Upcoming commercial milestones

    Upcoming commercial milestones For personal use only § Discovery Partnerships – Genentech II (2014/15) – New discovery alliances – Cosmeceu.cal out-­‐license (Biolink) § Oncology programme – Early 2015: In vitro data – important early-­‐stage partnering opportunity. – Late 2015: In vivo data -­‐ L

19. Slide 19: A Big Thankyou To All PYC Staff

    For personal use only A Big Thankyou To All PYC Staff!!!!! 19

20. Slide 20: Summary

    Summary § World leaders in pep.de-­‐based intracellular drug delivery For personal use only § Combined with Phylogica’s powerful Drug Discovery technology to develop fully-­‐integrated drug development plaTorm § Transi.oning from plaTorm to product focussed company § Well posi.oned to create mul

21. Slide 21: Contact Details

    Dr. Richard Hopkins Contact Details Dr. Paul WaQ Chief Execu7ve Officer Chief Scien7fic Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 For personal use only Fax: +61 8 9489 7700 Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.phylogic

Phylogica — Shareholder Meeting (November 2014) on 6ix